Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)
Charehbili, A., van de Ven, S., Smit, V. T. H. B. M., Meershoek-Klein Kranenbarg, E., Hamdy, N. A. T., Putter, H., Heijns, J. B., van Warmerdam, L. J. C., Kessels, L., Dercksen, M., Pepels, M. J., MaaVolume:
25
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdu102
Date:
May, 2014
File:
PDF, 168 KB
english, 2014
File converter
More search results
More benefits 
